Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I read something a few years ago about nano dots being used to deliver drugs. The original problem were they were cadmium based which meant they were highly toxic, but some were developed using non-cadmium materials. The drug is attached to the dots which are injected/digested to the correct area depending on treatment.
I don’t think TRX is about drug development their specialty is providing a mechanism to drug manufacturers to get their drug to the right area to make them more effective
Doesn’t TRX give NXP002 a possible second delivery system, so not only inhaled as it has a mechanism to direct the drug to the specific need. As far as we are aware it is not in the frame for NXP002 atm but there is no reason why it would not be an advantage rather than a hindrance. NXP002 is the only Tranilast under IP
I think Dan will steer clear of Tranilast as he has been burned trying to get a deal for it already and he has a vested interest for NFX to succeed with NXP002.
His company however have 4 pipelines they are dealing with which should keep them busy enough.
DG will have a clear run because he knows one way or another there will be no NFX
Again , What can you say at the Q & A . There' s no future plan , You cant drag up old wood .
What was said ' We are on plan and time schedule '
For me thats Q4 .
Its simple nothing changes now you either sell up or hold .Dont moan cause you have what your got .
Soup, my point is that they might be able to target vanilla Tranilast. If so, then they already have a business model that might not infringe on our patents (for the reasons that you mention).
If the toxicity of vanilla Tranilast severely affects the liver then by-passing the liver and delivering via the lymphatic system may eliminate or reduce the toxicity.
It was just a thought, hopefully something that is not in DG's interests given his current holding. However, it might be something he would consider if NXP002 disappoints.
Hedging your bets, so to speak.
To add to this conversation, I cant see any reason why it would be in Dan's interest to frustrate nfx being as he still holds a good proportion of the company's stock. The work they are planning for OXL001 will only benefit us in improving speed to market and as unlocking milestones and potential royalties at a quicker pace than we would have expected, as well as further acheiving nfx stated aims in this deal of proving the validity of their approach for the purposes of what I would assume to be improving their negotiating position with nxp002 and nxp004
I believe Anne has steadied the ship and installed a plan .
in my view NPX002 was some where near but her plan imho was to present the finished product.
Time will . I know I have said it before but why would JH and DG hold if it was a dog that some seem to think .
I cant say how much but you will see a result now in November I am convinced and lets say five weeks ,
Anne did not hat and coat it , she is seeing this through . NPX004 is the bonus and might well be the make weight.
Personally I don't see this company existing after NPX002 result . It will go as a package.
NFX patents are for tranilast cocrystals, not for tranilast. They have created a new entity that is based on tranilast.
TRx delivery mechanism is not likely (to my little knowledge) to solve the toxicology problems of tranilast which is what NfX have achieved by the cocrystal process.
So no, for Dan to infringe on NFX patents, TRX would have to completely change business model.
DG does now work for a company that is partnered with Oxilio to see if their delivery mechanism can be used for OXL001, that is true. In this case it seems to be supporting the use NXP001 so does not appear to be a threat.
However, TRX's mechanism is aimed at improving delivery of small molecule drugs via the lymphatic system instead of the liver, thereby overcoming serious side-effects and absorption limitations associated with the liver. Does that sound familiar? Isn't Tranilast a small molecule drug?
https://go.drugbank.com/drugs/DB07615
If it is a different mechanism then what is to stop them working directly with Tranilast in the future and competing with NXP002 or even NXP004 for that matter without infringing any of our patents? Is it possible that they can overcome the limitations of oral tranilast without requiring an inhaler product that might require investment in a different manufacturing process? Are there any grounds to be concerned that they now have access to DG's expertise in these products?
“ Anne has done nothing but put us at least a year behind imo I’ll be happy to be proved wrong”
Ok… a year ago the company said that inhaled was the route forward for NXP002. Did you see a timeline at that point? Did you see anyone talking about inhaler feasibility studies being set up alongside pharmacokinetics and pharmacodynamic studies.
Did you see how studies would be taken through the non GLP stage through to good lab practice to close out phase 1?
Did the company have NXP002 formula ready for an inhaler feasibility?
Ok your right Anne hasn’t done anything as all this was in place before she came in, as you say she’s just sat around and written the occasional rns to keep you happy.
You seem to have taken leave of your senses for some reason Kane.
Kane, Dan hasn’t ‘practically taken’ NXP001 in any sense.
He works for a company that is being paid by Oxilio to see if their tech can be used as a delivery mechanism for the drug!
Read the article I posted, it’s very clear in there.
I get wound up like You Kane it's absolutely understandable, this has been so so disappointing. Luckily Soup is the voice of reason for me and his posts remind me why I hold, unfortunately this is where we are, waiting on data that is all that's going on. I can honestly see NFX being taken out next year and hopefully at a price waaaaay above where we are now.
Re: Allenby & Walbrook, I get very annoyed when there's silence but he's quite right, the board need to direct them, it's very annoying but that's where we are, again.
For all our sakes I hope we have positive data in November and a serious big player buying in forcing the SP up to where it should be.
It 'could' be a very good Christmas, fingers crossed.
“You’re really want to get rid of a seriously good CEO who has previously developed massive drugs and an inhalation simulation for GSK because you think you know their day to day routine better than them?”
It’s going to happen sooner than later so they may as well get it over with! It’s going to knock another 10/15 percent off the share price when announced so yeah I’d prefer they just got it over with!!
Have I touched a nerve there in regards to nxp001? That’s exactly what’s happened open your eyes!! It was you that made everyone aware!!
Anne has done nothing but put us at least a year behind imo I’ll be happy to be proved wrong
“ Even our old ceo has practically taken one of the products for peanuts? ”
Kane this tells us that you don’t even bother to read what’s posted.
Kane, yeah Brindley has just outsourced everything, because the CRO does everything yeah.
They know exactly what your drug is from day one, they design the strategy for testing all on their own without talking to the company. They get on with testing without any collaboration or changes and just come to you at the end with a pre written rns.
Yeah actually you’re right this pharma CEO job is a doddle, you just give it to someone else to do then twiddle your thumbs.
Seriously Kane, give your head a knock. You’re really want to get rid of a seriously good CEO who has previously developed massive drugs and an inhalation simulation for GSK because you think you know their day to day routine better than them?
“if you think that Brindley (who has previously developed a blockbuster $bn+ inhaler based drug) is sat around doing nothing then you clearly haven't a clue on what NFX is actually about.”
Sorry soup but for a company that has outsourced EVERYTHING (apparently public relations also) I do wonder exactly what if anything she does on a daily basis ? The market doesn’t think so
Come on you’ve been around long enough to see we’re all being taken for a ride. Even our old ceo has practically taken one of the products for peanuts? Why not disclose details why no broker update just ignore it and it will go away!!
It’s a joke and the problem is the uncertainty around the ceo. Feek the data it can wait they need to stabilise the ship then resume. Nfx are a laughing stock at the moment and until this issue is resolved it will stay that way.
I have a lot of respect for you for the time you put in here and how you help people more than the company does. But really it shouldn’t be a guessing game should it!
I have emailed the company and will share the response if I receive one that is.
Good luck all!!
Kane, if you think that Brindley (who has previously developed a blockbuster $bn+ inhaler based drug) is sat around doing nothing then you clearly haven't a clue on what NFX is actually about.
Brindley was brought in because she was exactly what the company needed, someone who could develop the drug from the base IP to something workable.
They cannot say anything on NXP004 as it could scupper any patent application, so rightly they are silent there.
They cannot say anything yet on NXP002 as they are building the complete data set, then its ready to go.
My only gripe is on NXP001 where I do believe they could be more open.
The company are doing exactly what they told you they would do. Nothing has changed. In your own words, if your not happy then sell up and move on.
IG current spread 1.19-1.35p. It’s a joke now.
Kaneonaim, I am with you on this post.
Yes it’s very frustrating. I have watched a recent interview from Anne today and she needs to get her head checked she claims the company is in a better position now to when she joined imo it’s a feeking mess and she should be embarrassed it’s got so bad.
SORT THIS MESS OUT. It’s the least she could do for 10k a month.
They need to sort this stupid ceo issue out imo the chairman should become temporary replacement ASAP-announce to market!! Let do nothing Anne go ASAP she’s obviously not contributing anything the sooner we replace the better
They need to get their broker to write an update including explanation about CEO and new deals for nxp001 including how much revenue it will bring (if anything)
Start some basic PR even if it’s a few tweets from their twitter about current news on ipf or advances.
Anything is currently better than what you are doing-which is NOTHING!!! All in my opinion as a shareholder who has seen £132k plus turned into £65k !!!
It’s beyond a joke now!!
I understand your frustration Kane.
It might simply be because they want to avoid the risk of letting something slip in the run up to results. It's a shame they got rid of the link to the Q&A on the website though, they could have referred enquiring investors to that for more information instead of just declining and pulling the shutters down. That said, perhaps the reason why they pulled that link is because there was something in it that shouldn't have been there in the first place.
Kane, Allenby and Wallbrook only do work when instructed by NFX, they are paid for specific work, not a continual expense.
So the fact they are silent is because the company isn’t telling them anything.
Not in the least bit surprised, it's like any emails to them, will be updated as and when